» Articles » PMID: 37352322

ELISA F29 -A Therapeutic Efficacy Biomarker in Chagas Disease: Evaluation in Pediatric Patients Treated with Nifurtimox and Followed for 4 Years Post-treatment

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Measurement of the success of antitrypanosomal treatment for Chagas disease is difficult, particularly in the chronic phase of the disease, because anti-Trypanosoma cruzi antibodies persist in serum for prolonged periods. We studied the effects of nifurtimox administered by two different treatment regimens on the T. cruzi calcium-binding flagellar protein F29 in children diagnosed with Chagas disease measured using an enzyme-linked immunosorbent assay (ELISA) technique (ELISA F29).

Methods And Principal Findings: In a phase 3, randomized, double-blind, parallel-group, historically controlled study (ClinicalTrials.gov NCT02625974), blood samples obtained from children diagnosed with Chagas disease and treated with nifurtimox for either 60 days or 30 days were analyzed using an ELISA with an F29 recombinant protein as the antigen, as well as conventional serological tests (recombinant ELISA and indirect hemagglutination assay). In an exploratory approach, serological response to nifurtimox treatment was evaluated for 4 years post-treatment. In both treatment groups, the number of patients with negative ELISA F29 values increased over the period of observation. The incidence rate of negative seroconversion using ELISA F29 was 22.94% (95% CI: 19.65%, 26.63%) in the 60-day treatment group and 21.64% (95% CI: 17.21%, 26.86%) in the 30-day treatment group. In the subpopulation of patients who tested seropositive for F29 before nifurtimox treatment, 88 patients (67.7%) in the 60-day regimen and 39 patients (59.1%) in the 30-day regimen were F29 seronegative at 4 years post-treatment. All patients who had a positive ELISA F29 test at baseline and seroconverted to negative measured by conventional serology reached seronegativity in ELISA F29 earlier than in conventional serology.

Conclusions: The results demonstrate a serological response to treatment with nifurtimox measured by the ELISA F29 test in children diagnosed with Chagas disease. The F29-based ELISA can be considered a potential early marker of response to antitrypanosomal therapy for Chagas disease.

Trial Registration: ClinicalTrials.gov NCT02625974.

Citing Articles

Redefining the treatment of Chagas disease: a review of recent clinical and pharmacological data for a novel formulation of nifurtimox.

Altcheh J, Grossmann U, Stass H, Springsklee M, Garcia-Bournissen F PLoS Negl Trop Dis. 2025; 19(2):e0012849.

PMID: 39999088 PMC: 11856279. DOI: 10.1371/journal.pntd.0012849.


Circulating extracellular vesicles in sera of chronic patients as a method for determining active parasitism in Chagas disease.

Lozano N, Prescilla-Ledezma A, Calabuig E, Trelis M, Arce J, Lopez Hontangas J PLoS Negl Trop Dis. 2024; 18(11):e0012356.

PMID: 39565824 PMC: 11616892. DOI: 10.1371/journal.pntd.0012356.


Listen to what the animals say: a systematic review and meta-analysis of sterol 14-demethylase inhibitor efficacy for in vivo models of Trypanosoma cruzi infection.

Bisio M, Medina L, Garcia-Bournissen F, Gulin J Parasitol Res. 2024; 123(6):248.

PMID: 38904688 DOI: 10.1007/s00436-024-08257-3.


An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study.

Abal M, Balouz V, Lopez R, Giorgi M, Marino C, Cruz C PLoS Negl Trop Dis. 2024; 18(1):e0011910.

PMID: 38236916 PMC: 10826959. DOI: 10.1371/journal.pntd.0011910.


Secreted Cyclophilin CyP19 as an Early Marker for Trypanocidal Treatment Efficiency.

Perrone A, Pinillo M, Rial M, Fernandez M, Milduberger N, Gonzalez C Int J Mol Sci. 2023; 24(15).

PMID: 37569250 PMC: 10418876. DOI: 10.3390/ijms241511875.

References
1.
Fabbro D, Velazquez E, Bizai M, Denner S, Olivera V, Arias E . Evaluation of the ELISA-F29 test as an early marker of therapeutic efficacy in adults with chronic Chagas disease. Rev Inst Med Trop Sao Paulo. 2013; 55(3). DOI: 10.1590/S0036-46652013000300005. View

2.
Perez-Molina J, Molina I . Chagas disease. Lancet. 2017; 391(10115):82-94. DOI: 10.1016/S0140-6736(17)31612-4. View

3.
Ademar Sales Junior P, Molina I, Murta S, Sanchez-Montalva A, Salvador F, Correa-Oliveira R . Experimental and Clinical Treatment of Chagas Disease: A Review. Am J Trop Med Hyg. 2017; 97(5):1289-1303. PMC: 5817734. DOI: 10.4269/ajtmh.16-0761. View

4.
Porcel B, Bontempi E, Henriksson J, Rydaker M, Aslund L, Segura E . Trypanosoma rangeli and Trypanosoma cruzi: molecular characterization of genes encoding putative calcium-binding proteins, highly conserved in trypanosomatids. Exp Parasitol. 1996; 84(3):387-99. DOI: 10.1006/expr.1996.0127. View

5.
Fabbro D, Streiger M, Arias E, Bizai M, Barco M, Amicone N . Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop. 2007; 40(1):1-10. DOI: 10.1590/s0037-86822007000100001. View